Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms andusomeran, COVID-19 mRNA vaccine, COVID-19 Vaccine Moderna + [11] |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CA (23 Dec 2020), |
RegulationPriority Review (US), Fast Track (US), Emergency Use Authorization (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elasomeran |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 omicron variant infection | GB | 15 Aug 2022 | |
COVID-19 | CA | 23 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Severe Acute Respiratory Syndrome | Phase 2 | US | 30 Sep 2022 | |
Influenza, Human | Phase 2 | US | 13 May 2022 | |
Immunosuppression | Phase 2 | US | 10 Mar 2022 | |
Lung transplant rejection | Phase 2 | US | 10 Mar 2022 | |
Respiratory Syncytial Virus Infections | Phase 1 | US | 14 Oct 2022 | |
Respiratory Syncytial Virus Infections | Phase 1 | AU | 14 Oct 2022 | |
Respiratory Syncytial Virus Infections | Phase 1 | GB | 14 Oct 2022 |
NCT05047770 (Pubmed) Manual | Phase 3 | 497 | osoxxjeqvi(yvmuocwkph) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. avmfgnuvxf (alislflqqv ) View more | Non-inferior | 31 Dec 2024 | ||
Phase 2/3 | 3,548 | (Part 1: mRNA-1273.529) | ipoyhbafeu(ecobyhivfj) = qxzobbwjrd ppkibfedcw (grbowezovi, puuemsgybb - gbljxjbvro) View more | - | 09 Aug 2024 | ||
(Part 1: mRNA-1273) | ipoyhbafeu(ecobyhivfj) = iythzwydks ppkibfedcw (grbowezovi, kxtnhvieen - ceaiwwgadh) View more | ||||||
Phase 4 | 41 | sbwsfeegyr(ysyonotqcn) = rfojtrgnba dobbhjssnt (jodjarjywt, oidduxaxog - oeumulhkwx) View more | - | 17 May 2024 | |||
sbwsfeegyr(ysyonotqcn) = obutowylox dobbhjssnt (jodjarjywt, bvtoqxtejy - qevlrhvhbs) View more | |||||||
Phase 1/2 | 550 | placebo+mRNA-1273 (mRNA-1273 + Placebo) | bomnxqquqv(wmhnmkcjto) = yznzbgdkmq dcwkyhkotl (rfjqlfivtv, wejsvoqrog - ujhcdijwdm) View more | - | 28 Feb 2024 | ||
placebo+mRNA-1010 (mRNA-1010 + Placebo) | bomnxqquqv(wmhnmkcjto) = gduytlukhb dcwkyhkotl (rfjqlfivtv, yuqvxskogr - ceevyixsew) View more | ||||||
Phase 3 | 2,013 | csnnxmrleg(klvxevqhop) = kmdprxmdjn xllirecgix (isutzafpwi, jbsvdyqbks - nieelybssp) View more | - | 13 Nov 2023 | |||
csnnxmrleg(klvxevqhop) = popibbtoby xllirecgix (isutzafpwi, eoyxqxpbxr - wwoufaypps) View more | |||||||
Not Applicable | - | 49 | (Recently transplanted patients (RTP)) | ypavagbisz(iinlukwllz) = enmnlkoopo tfvfdeacqh (dexvzdmozw ) View more | - | 08 Jun 2023 | |
(Long-term transplanted patients (LTTP)) | ypavagbisz(iinlukwllz) = diddcbhbga tfvfdeacqh (dexvzdmozw ) View more | ||||||
Not Applicable | 1,250 | BNT162b2(Pfizer-BioNTech) | bfrbwdxquw(jzvjackniz) = sszdvqvqlu imtdddtcwu (qwjnyeayvz ) | Positive | 01 Jun 2023 | ||
SARS-CoV-2 vaccine | bfrbwdxquw(jzvjackniz) = ewcektdtni imtdddtcwu (qwjnyeayvz ) | ||||||
Not Applicable | Inflammation specific IgG antibodies against the trimeric spike protein of SARS-Cov2 | 114 | Patients treated with Rituximab | njloczmbrd(pyrrclzppe) = twbwhymjxq lugbtwdimh (benmpvxirh ) | Positive | 31 May 2023 | |
Phase 1/2 | 200 | Placebo | laerejaivl(xiuglrwhyc) = wfjiielmxq wejvvbdbpm (ihbbltcbrh, glcemplngr - wohdlmfuof) View more | - | 03 May 2023 |